Premium Nahrungsergänzungsmittel | artgerecht

Keytruda (Pembrolizumab) – Uses, Mechanism & Side Effects

Keytruda (pembrolizumab) is a cancer medication and immune checkpoint inhibitor that helps the immune system detect and destroy tumor cells.

Regular tips about health Regular tips about health

Things worth knowing about "Keytruda"

Keytruda (pembrolizumab) is a cancer medication and immune checkpoint inhibitor that helps the immune system detect and destroy tumor cells.

What is Keytruda?

Keytruda is the brand name for pembrolizumab, a monoclonal antibody classified as an immune checkpoint inhibitor. It is manufactured by MSD (Merck Sharp & Dohme) and is widely used in oncology. Keytruda has received approval from both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for a broad range of cancer indications, making it one of the most widely approved cancer immunotherapies in the world.

Mechanism of Action

The immune system uses checkpoints to prevent itself from attacking healthy tissue. Cancer cells exploit this mechanism by expressing a protein called PD-L1 (Programmed Death-Ligand 1) on their surface, which essentially makes them invisible to immune cells.

Pembrolizumab works by blocking the PD-1 (Programmed Cell Death Protein 1) receptor found on T-lymphocytes (immune cells). By blocking this receptor, the suppressive signal is removed, allowing T-cells to recognize and attack tumor cells once again.

Approved Indications

Keytruda is approved for a wide range of cancers, including:

Non-small cell lung cancer (NSCLC) – as first- or second-line therapy
Melanoma – in advanced or metastatic stages
Triple-negative breast cancer
Urothelial carcinoma (bladder cancer)
Head and neck squamous cell carcinoma (HNSCC)
Colorectal cancer with high microsatellite instability (MSI-H)
Cervical cancer
Endometrial carcinoma
Gastric and esophageal cancer
Hepatocellular carcinoma (liver cancer)
Other tumor types in combination with additional therapies

Dosage and Administration

Keytruda is administered as an intravenous (IV) infusion, typically over 30 minutes. The standard dosing regimens are:

200 mg every 3 weeks or
400 mg every 6 weeks

The exact dosage and treatment plan are determined individually by the treating oncologist based on the type and stage of cancer and the overall health of the patient. Treatment may continue for several months to years.

Side Effects

Because Keytruda activates the immune system, it can cause immune-related adverse events (irAEs), which can potentially affect almost any organ. Common side effects include:

Fatigue and weakness
Skin rash and itching
Diarrhea and colitis (intestinal inflammation)
Pneumonitis (lung inflammation)
Thyroid disorders (hypothyroidism or hyperthyroidism)
Hepatitis (liver inflammation)
Nephritis (kidney inflammation)
Hormonal disorders (endocrinopathies)

Severe immune-related side effects require prompt medical management, usually with corticosteroids (e.g., prednisone) to suppress the excessive immune response. In some cases, treatment with Keytruda must be paused or permanently discontinued.

Biomarkers and Patient Selection

Not all patients respond equally well to Keytruda. A key predictive biomarker is PD-L1 expression in the tumor, which is measured from a tissue sample (biopsy). Higher PD-L1 expression generally correlates with a better response to treatment. Additional biomarkers such as tumor mutational burden (TMB) and microsatellite instability (MSI) can also guide patient selection.

Combination Therapies

Keytruda is frequently used in combination with other cancer treatments, including:

Chemotherapy (e.g., platinum-based regimens)
Other targeted therapies (e.g., tyrosine kinase inhibitors)
Antiangiogenic agents (e.g., bevacizumab, lenvatinib)

These combination approaches can enhance treatment efficacy but may also increase the risk of side effects, requiring close monitoring by the medical team.

References

European Medicines Agency (EMA): Keytruda (pembrolizumab) – Product information and approval status. Available at: https://www.ema.europa.eu
Brahmer, J. R. et al. (2022): Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy. Journal of Clinical Oncology, 40(12), 1370–1399.
Robert, C. et al. (2021): Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006). New England Journal of Medicine, 372(26), 2521–2532.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.